|
Zeidan, Amer M; Ricklis, Rebecca M; Carraway, Hetty E et al. (2012) Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. Br J Haematol 158:198-207
|
|
Karp, Judith E; Smith, B Douglas; Resar, Linda S et al. (2011) Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117:3302-10
|
|
Fathi, Amir T; Grant, Steven; Karp, Judith E (2010) Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 36:142-50
|
|
Karp, Judith E; Blackford, Amanda; Smith, B Douglas et al. (2010) Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res 34:877-82
|
|
Fathi, Amir T; Karp, Judith E (2009) New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep 11:346-52
|
|
Karp, Judith E; Smith, B Douglas; Gojo, Ivana et al. (2008) Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 14:3077-82
|
|
Gojo, Ivana; Jiemjit, Anchalee; Trepel, Jane B et al. (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109:2781-90
|
|
Lancet, Jeffrey E; Gojo, Ivana; Gotlib, Jason et al. (2007) A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109:1387-94
|
|
Badros, Ashraf Z; Goloubeva, Olga; Rapoport, Aaron P et al. (2005) Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 23:4089-99
|
|
Bauer, Kenneth S; Karp, Judith E; Garimella, Tushar S et al. (2005) A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leuk Res 29:263-71
|
Showing the most recent 10 out of 25 publications
